Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Chronic Spontaneous Urticaria
Interventions: Ligelizumab, Omalizumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 30
States / cities: Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more

Conditions: Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atopic Dermatitis
Interventions: pimecrolimus, topical medical device; Drug · Device
Lead sponsor: Emer, Jason, M.D.; Individual
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Dermatitis, Contact
Interventions: T.R.U.E. Test; Biological
Lead sponsor: Allerderm; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Melanoma (Skin)
Interventions: reverse transcriptase-polymerase chain reaction, sentinel lymph node biopsy; Genetic · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: Not listed
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
Interventions: Skin Taping, Blood Sampling, Skin Biopsy; Procedure
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 12,343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: ruxolitinib cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 30
States / cities: Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more

Conditions: Atopic Dermatitis
Interventions: ASN002; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 31
States / cities: Anniston, Alabama • Birmingham, Alabama • Fremont, California + 25 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Tdap vaccine, PPS vaccine; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more

Conditions: Hereditary Angioedema (HAE)
Interventions: icatibant; Drug
Lead sponsor: Shire; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • Tampa, Florida • Shreveport, Louisiana + 9 more

Conditions: Epidermolysis Bullosa, Ichthyosis, Atopic Dermatitis, Psoriasis
Interventions: TheraClean; Device
Lead sponsor: Northwestern University; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanocytic Nevus
Interventions: Skin Spect dermoscope, Spatially modulated quantitative; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Irvine, California

Conditions: Atopic Dermatitis
Interventions: NM26-2198, Placebo; Biological · Other
Lead sponsor: Yellow Jersey Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Fountain Valley, California • Glendale, California • San Diego, California + 3 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Ligelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 1,033 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 39
States / cities: Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more

Conditions: Cryopyrin-Associated Periodic Syndrome
Interventions: ATI-450; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: San Diego, California • San Francisco, California

Conditions: Allergic Rhinitis
Interventions: saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol; Drug
Lead sponsor: Bryan Martin, DO; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Atopic Dermatitis, Eczema
Interventions: Current standard eczema treatment and standard pillow at night, Chillow cooling pillow; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Milk and/or Peanut Allergy
Interventions: Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk); Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hereditary Angioedema (HAE)
Interventions: C1 esterase inhibitor [human] liquid, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more

Conditions: Atopic Dermatitis
Interventions: MEDI9929, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: North Miami Beach, Florida • Tampa, Florida • Arlington Hts, Illinois + 5 more

Conditions: Atopic Dermatitis
Interventions: Tencel Therapeutic Garments, Cotton Therapeutic Garments; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Months to 6 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: ASN002, Placebo Oral Tablet; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 30
States / cities: Anniston, Alabama • Birmingham, Alabama • Fremont, California + 24 more

Conditions: Hereditary Angioedema
Interventions: C1 Esterase Inhibitor; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 6 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 13
States / cities: Weston, Florida • Atlanta, Georgia • Idaho Falls, Idaho + 10 more

Search by objective public record fields.

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Supplemental Oxygen in Pulmonary Fibrosis

Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents

Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma

Pilot Tape Harvesting Study

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Thera-Clean® Microbubbles System in Patients With Skin Diseases

Comparison Imaging System Between Spatially Modulated Quantitative Spectroscopy and Skin Spect Dermoscopy

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests

Cooling Pillow for Atopic Dermatitis

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

Tencel vs. Standard Cotton Therapeutic Garments as an Adjunct Treatment for Moderate to Severe Atopic Dermatitis in Children

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)